129 related articles for article (PubMed ID: 20464599)
21. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
Cabarrocas X;
Clin Ther; 2001 Nov; 23(11):1867-75. PubMed ID: 11768838
[TBL] [Abstract][Full Text] [Related]
22. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
23. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
Dodick DW; Tepper SJ; Friedman DI; Gelfand AA; Kellerman DJ; Schmidt PC
Headache; 2018 Jul; 58(7):986-992. PubMed ID: 29782049
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Silberstein SD; Elkind AH; Schreiber C; Keywood C
Neurology; 2004 Jul; 63(2):261-9. PubMed ID: 15277618
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies.
Allais G; Tullo V; Omboni S; Benedetto C; Sances G; Zava D; Ferrari MD; Bussone G
Neurol Sci; 2012 May; 33 Suppl 1(Suppl 1):S65-9. PubMed ID: 22644174
[TBL] [Abstract][Full Text] [Related]
28. Variability of the characteristics of a migraine attack within patients.
Viana M; Sances G; Ghiotto N; Guaschino E; Allena M; Nappi G; Goadsby PJ; Tassorelli C
Cephalalgia; 2016 Aug; 36(9):825-30. PubMed ID: 26498348
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
30. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
32. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Eur Neurol; 2005; 53 Suppl 1():41-8. PubMed ID: 15920337
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2007 Sep; 47(8):1169-77. PubMed ID: 17883521
[TBL] [Abstract][Full Text] [Related]
34. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
35. An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients.
Chae D; Park K
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):721-731. PubMed ID: 30043250
[TBL] [Abstract][Full Text] [Related]
36. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
Mathew NT;
Headache; 2002 Jan; 42(1):32-40. PubMed ID: 12005273
[TBL] [Abstract][Full Text] [Related]
37. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan.
Dowson AJ; Massiou H; Aurora SK
J Headache Pain; 2005 Apr; 6(2):81-7. PubMed ID: 16362647
[TBL] [Abstract][Full Text] [Related]
38. Migraine with aura versus migraine without aura: pain intensity and associated symptom intensities after placebo.
Bigal ME; Bordini CA; Sheftell FD; Speciali JG; Bigal JO
Headache; 2002 Oct; 42(9):872-7. PubMed ID: 12390612
[TBL] [Abstract][Full Text] [Related]
39. Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safety.
Charles JA
J Headache Pain; 2006 Apr; 7(2):95-7. PubMed ID: 16688412
[TBL] [Abstract][Full Text] [Related]
40. Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine.
Mathew NT
Clin Ther; 2002 Apr; 24(4):520-9. PubMed ID: 12017397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
